Celltrion

Celltrion, a Pharmaceutical Preparation Manufacturing company based in KR, reported its 2024 emissions at approximately 121,599,000 kg CO2e. This includes Scope 1 emissions of 27,146,000 kg CO2e, Scope 2 emissions (location-based) of 52,028,000 kg CO2e, and Scope 3 emissions of 42,426,000 kg CO2e. Key categories within Scope 3 for 2024 were upstream transportation and distribution at 18,122,000 kg CO2e and downstream transportation and distribution at 26,939,000 kg CO2e.

In 2023, the company's Scope 1 emissions were 22,457,000 kg CO2e, Scope 2 emissions (location-based) were 42,260,000 kg CO2e, and Scope 3 emissions totalled 28,798,000 kg CO2e. For 2022, Celltrion reported Scope 1 emissions of 21,218,000 kg CO2e and Scope 2 emissions (location-based) of 35,299,000 kg CO2e, with no Scope 3 data available for that year. In 2021, Scope 1 emissions were 19,402,000 kg CO2e and Scope 2 emissions (location-based) were 35,213,000 kg CO2e. For 2020, Celltrion's Scope 1 emissions were 18,297,000 kg CO2e and Scope 2 emissions were 34,305,000 kg CO2e. In 2019, Scope 1 emissions were 16,864,000 kg CO2e and Scope 2 emissions were 31,667,000 kg CO2e.

Celltrion is committed to reducing its carbon footprint. The company has set a goal to reduce its overall greenhouse gas emissions by 50% by 2030, compared to 2020 levels. Furthermore, Celltrion aims to achieve carbon neutrality by 2050. The company has also announced a Net Zero commitment to mitigate Scope 1 and 2 emissions across its domestic operations by 42% by 2030 and by 100% by 2045, using 2022 as the base year.